The FDA Issues the 2022 Drug Safety Priorities Annual Report

The CDER Drug Safety Priorities 2022 report, emphasizes key safety-related meetings and achievements of this necessary work, including the many ways CDER has strived to be involved in facilitating and protecting public health amid the ongoing SARS-CoV-2 coronavirus (COVID-19) pandemic and via their ongoing efforts associated with non-medical use of opioids and other controlled substances.

The report is concentrated on the programs and initiatives at the core of CDER’s drug safety operations, including the FDA Adverse Event Reporting System, the Sentinel System, and the Safe Use Initiative.

It furthermore features ongoing activities to battle the national drug overdose crisis, including the establishment of the FDA’s Overdose Prevention Framework.

The report details CDER’s efforts to enhance the general quality of compounded drugs and work to manage unexpected – and potentially cancer-causing – impurities in medications. It also spotlights communications to transparently convey drug safety information to the public through, different tools such as Drug Safety Communications and research to better understand drug safety risks.

 Learn More

Written by Anita Johnson-Brown

More News from Los Angeles

• News Mix Top News
• Anita Brown's commentary Opinions matter